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Abstract
OBJECTIVE: To estimate the risk of stillbirth (fetal death at 20 weeks of gestation or more) 
associated with specific birth defects.
METHODS: We identified a population-based retrospective cohort of neonates and fetuses with 
selected major birth defects and without known or strongly suspected chromosomal or single-gene 
disorders from active birth defects surveillance programs in nine states. Abstracted medical 
records were reviewed by clinical geneticists to confirm and classify all birth defects and birth 
defect patterns. We estimated risks of stillbirth specific to birth defects among pregnancies overall 
and among those with isolated birth defects; potential bias owing to elective termination was 
quantified.
RESULTS: Of 19,170 eligible neonates and fetuses with birth defects, 17,224 were liveborn, 852 
stillborn, and 672 electively terminated. Overall, stillbirth risks ranged from 11 per 1,000 fetuses 
with bladder exstrophy (95% CI 0–57) to 490 per 1,000 fetuses with limb-body-wall complex 
(95% CI 368–623). Among those with isolated birth defects not affecting major vital organs, 
elevated risks (per 1,000 fetuses) were observed for cleft lip with cleft palate (10; 95% CI 7–15), 
transverse limb deficiencies (26; 95% CI 16–39), longitudinal limb deficiencies (11; 95% CI 3–
28), and limb defects due to amniotic bands (110; 95% CI 68–171). Quantified bias analysis 
suggests that failure to account for terminations may lead to up to fourfold underestimation of the 
observed risks of stillbirth for sacral agenesis (13/1,000; 95% CI 2–47), isolated spina bifida 
(24/1,000; 95% CI 17–34), and holoprosencephaly (30/1,000; 95% CI 10–68).
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CONCLUSION: Birth defect-specific stillbirth risk was high compared with the U.S. stillbirth 
risk (6/1,000 fetuses), even for isolated cases of oral clefts and limb defects; elective termination 
may appreciably bias some estimates. These data can inform clinical care and counseling after 
prenatal diagnosis.
Major birth defects are common, occurring in one in every 33 pregnancies in the United 
States.1 Birth defects are a known risk factor for stillbirth, are identified in one in every five 
stillborn fetuses, and are thus a major contributor to the stillbirth rate in the United States 
(6/1,000 fetuses in the general U.S. population; approximately 4,600 annual stillbirths with 
major birth defects).2–4 Yet, little information is available on risk of stillbirth associated with 
most specific birth defects.5–7
Estimates of stillbirth risk are needed to inform clinical care and parent counseling after 
prenatal diagnosis of birth defects.8,9 Prior research has suggested that enhanced prenatal 
monitoring of fetuses with gastroschisis may reduce stillbirth risk.10–14 Robust estimates for 
a wide range of defects could identify other birth defects for which enhanced monitoring 
might be indicated.
The generation of accurate stillbirth risk estimates is complicated by the difficulty in 
identifying a sufficient number of well-characterized birth defect cases in both live birth and 
stillbirths, as well as in pregnancies ending in terminations. Compared with those with more 
moderate prenatally diagnosed birth defects, in the United States the odds of elective 
termination are 126 times higher for fetuses with severe non-neurologic birth defects and 
more than 300 times higher for fetuses with serious neurologic malformations.15 Therefore, 
conventional estimates that do not account for elective termination owing to prenatal 
diagnosis of birth defects may underestimate stillbirth risks; this potential bias has not been 
quantified.16–19
We estimated birth defect-specific risk of stillbirth among fetuses with selected birth defects 
and quantified the potential bias owing to elective termination of pregnancy using data on 
more than 19,000 birth defect cases identified by the National Birth Defects Prevention 
Study.
METHODS
We used data from the retrospective cohort of birth defect cases that underlies the National 
Birth Defects Prevention Study, a large, population-based collaborative, multistate, case–
control study of selected major birth defects (Appendices 1 and 2, available online at http://
links.lww.com/AOG/B669) in the United States from 1997 to 2011.20 Briefly, birth defect 
cases were identified using active case-finding methods by population-based surveillance 
systems in 10 states (Arkansas, California, Georgia, Iowa, Massachusetts, North Carolina, 
New Jersey, New York, Texas, and Utah).21 Within their respective catchment areas, each 
site abstracted and reviewed medical records for all potentially eligible surveillance-
identified birth defect cases; records of all identified stillborn fetuses were reviewed for birth 
defects. Abstracted medical records for all identified birth defect cases were reviewed by 
clinical geneticists at each site to confirm each reported birth defect diagnosis. Institutional 
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Review Board approval was obtained by all study sites; individual consent was not required 
for the collection or analysis of data under these approvals.
Birth defect cases with a known or strongly suspected single gene or chromosomal disorder 
were ineligible for the National Birth Defects Prevention Study; genetic studies were not 
required. We excluded cases without confirmatory testing if review by board-certified 
geneticists identified features (eg, a pattern of major or minor anomalies, family history of 
disorder with known genetic basis) strongly suggested that the presence of a chromosomal 
or genetic disorder. Cases with the following pregnancy outcomes were eligible for inclusion 
in the study: live birth (any gestational age), pregnancy termination (any gestational age), or 
stillbirth (defined as a spontaneous fetal death at 20 weeks of gestation or more or a birth 
weight of 500 g or more). Spontaneous losses at less than 20 weeks of gestation were 
ineligible.
Cases were further reviewed by study clinical geneticists to confirm that each National Birth 
Defects Prevention Study–eligible birth defect case met standard criteria and to classify the 
birth defect pattern according to a standard algorithm.22 Cases classified as “isolated” may 
have a single major birth defect, a primary birth defect with other resulting defects (eg, a 
fetus with hydrocephalus and clubbed feet due to spina bifida and no other defects), or a 
series of birth defects caused by a common disruption of development (eg, limb-body-wall 
complex). Fetuses with a defect classification other than “isolated” were categorized as 
having multiple birth defects.
We excluded cases with an unknown pregnancy outcome, a gestational age not reliably 
determined to be greater than or less than 20 weeks, live births or terminations at less than 
20 weeks of gestation, and cases from study sites that enrolled only live births (New York 
before 2000, New Jersey); cases from study sites not enrolling terminations were included 
(Georgia before 1999, Massachusetts all years) resulting in analyses among nine states20 
(Fig. 1). Gestational age was obtained from medical or vital records or maternal report (for 
interviewed cases) and reviewed for consistency with birth weight and pregnancy outcome 
(details are described in Appendix 3, available online at http://links.lww.com/AOG/B669).
We excluded from our analyses those National Birth Defects Prevention Study–eligible birth 
defects which are most often diagnosed based on postnatal signs or symptoms (ie, biliary, 
small intestinal, colonic, or anorectal atresia and craniosynostosis), poorly identified 
prenatally and require autopsy or postnatal studies to confirm (ie, cerebellar hypoplasia), 
difficult to observe on physical exam in small or macerated fetuses (ie, hypospadias, 
glaucoma, cataracts, anophthalmia or microphthalmia, anotia or microtia, and choanal 
atresia), or poorly defined (ie, limb deficiency, not otherwise stated).23–25 We further 
excluded isolated heart defects based on the low sensitivity of prenatal diagnosis during the 
study period and incomplete cardiology review for a subset of heart defect cases with high 
detection (eg, hypoplastic left heart syndrome).23,26–29
We considered the birth defect case population to be a cohort of fetuses with birth defects at 
risk of stillbirth (gestational age at delivery 20 weeks or more or birth weight 500 g or 
more). We calculated absolute birth defect-specific risk as the number of stillbirths divided 
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by the total number of live births and stillbirths with that defect. We then calculated 
estimates after restricting first to cases without a lethal birth defect (ie, limb-body-wall 
complex, anencephaly, agyria, hydranencephaly, vein of Galen malformation, tracheal 
atresia, bilateral renal agenesis), and second to isolated cases. For multiple major birth 
defects cases, the number of stillbirths, live births, and termination for specific birth defects 
are reported in Appendix 4, available online at http://links.lww.com/AOG/B669. Cases were 
included in analyses for each primary birth defect meeting study inclusion criteria. For 
example, a fetus categorized as “isolated spina bifida” who also had hydrocephalus due to 
the spina bifida would be included only in the spina bifida analysis in the “overall,” 
“nonfatal” and “isolated” analyses. A fetus with cleft palate and a heart defect would be 
included in the “overall” and “nonfatal” cleft palate analyses but excluded from the 
“isolated” analysis.
Risks were calculated when there were at least 10 fetuses with a specific birth defect in the 
category of interest. We calculated two-tailed 95% CIs using the Poisson distribution when 
there were fewer than 20 stillbirths and using the exact binomial method otherwise.
We quantified the possible effect of termination of birth defect cases by estimating the lower 
and upper bounds of the possible birth defect-specific risk given our observed data without 
additional assumptions.30 To do so, we calculated the risk of stillbirth after setting the 
outcome of terminated cases at their most extreme values: the lower bound was estimated 
with all elective terminations included in the denominator (calculated as the number of 
stillbirths divided by the total number with all outcomes [liveborn, stillborn, terminated]); 
the upper bound was estimated with all terminations included in the numerator and 
denominator (the number of stillborn cases plus all cases ending in termination, divided by 
the total number of outcomes). Note that both extremes are unrealistic and just meant to 
provide bounds of the stillbirth risk in the absence of any terminations: ie, the first (lower 
limit) had none of the terminations been stillbirths and the second (upper limit) had all been 
stillborn.
Terminations before 20 weeks of gestation may also remove high-risk fetuses from the 
population at risk of stillbirth; however, had the pregnancy continued, some would have been 
miscarried before 20 weeks of gestation. As a sensitivity analysis, we estimated risk bounds 
including all terminations for the overall analysis, regardless of gestational age, and 
calculated the absolute and change in the upper and lower risk bounds.
Risk estimates, bounds, and 95% CIs are reported as stillbirths per 1,000 birth defect cases. 
All analyses were conducted by the first author using SAS 9.4.
RESULTS
Of the 19,170 cases included in our analytic cohort (Fig. 1), 89.8% were liveborn (17,224), 
4.4% were stillborn (n5852), and 3.5% (n5672) underwent termination for birth defects after 
20 weeks of gestation. Most fetuses and neonates (79%, n515,198) had an isolated birth 
defect.
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We report overall stillbirth risk estimates, bounds, and 95% CIs by specific birth defect in 
Figure 2. Stillbirth risk exceeded 40% for limb-body-wall complex (490/1,000 fetuses; 
[30/61 cases, risk bound: 320–670; 95% CI 368–623]) and anencephaly (420/1,000; 
[261/625 cases, risk bound: 300–590; 95% CI 379–457]) and was 230 per 1,000 for bilateral 
renal agenesis (64/276 cases; risk bound: 190–360; 95% CI 184–286), all of which are fatal 
by the end of the neonatal period (“perinatal lethal” defects). Additionally, risk estimates 
exceeded 10% for omphalocele (110/1,000 [68/589 cases; risk bound: 110–160; 95% CI 91–
144]) and amniotic band syndrome including craniofacial anomalies (130/1,000 [9/72 cases; 
risk bound: 110–250; 95% CI 60–224]) or with limb anomalies only (140/1,000 [47/344 
cases; risk bound: 140–140; 95% CI 102–178]). The birth defect with the lowest risk 
estimate was bladder exstrophy (11/1,000 [1/95 cases; risk bound: 11–11; 95% CI 0–57). 
Seven defects had a stillbirth risk and upper risk bound less than 20 per 1,000 affected 
fetuses. Although sacral agenesis had a stillbirth risk of 13 per 1,000 (2/152 cases; 95% CI 
2–47), the upper risk bound was four times higher (57/1,000) than the observed risk after 
accounting for the potential effect of terminations.
After restricting to cases with nonfatal defects most stillbirth risk estimates and risk bounds 
did not change from those among all cases (Appendix 5, available online at http://
links.lww.com/AOG/B669). However, the following stillbirth risk estimates (per 1,000) were 
reduced: omphalocele (from 115 to 105), sacral agenesis (13–7), and transverse and 
longitudinal limb deficiencies (41–36 and 25–21, respectively). Additionally, the risk bounds 
narrowed for these defects and others.
We present stillbirth risk estimates, bounds, and 95% CIs among fetuses with isolated birth 
defects by specific birth defect in Figure 3. Either no stillbirths or only one stillbirth 
occurred among the isolated cases of three defects: sacral agenesis (n=17), intercalary limb 
deficiency (n=61), and bladder exstrophy (n=70). Compared with the overall analysis, risk 
estimates were decreased after restricting to isolated defects, with the exception of the 
perinatal lethal birth defects. Among those with isolated birth defects not affecting major 
vital organs, risks of 10 per 1,000 or greater were found for cleft lip with cleft palate 
(10/1,000 [25/2,384 cases; risk bound: 10–10; 95% CI 7–15]), transverse limb deficiencies 
(26/1,000 [22/845 cases; risk bound: 11–24; 95% CI 16–39]), longitudinal limb deficiencies 
(11/1,000 [4/368 cases; risk bound: 11–24; 95% CI 3–28]), and limb defects due to amniotic 
bands (110/1,000 [18/161 cases; risk bound: 111–117; 95% CI 68–171]). Quantified bias 
estimates suggest that risk of stillbirth for isolated spina bifida (24/1,000 [33/1,347 cases; 
risk bound: 22–108; 95% CI 17–34]) and holoprosencephaly (30/1,000 [5/167 cases; risk 
bound: 27–120; 95% CI 10–68]) may be up to four times higher than observed risks after 
accounting for the potential effect of terminations.
Fewer than half (39%) of all elective terminations occurred before 20 weeks of gestation 
(n=422/1,094 total), but the proportion varied by specific defect (Appendix 6, available 
online at http://links.lww.com/AOG/B669). After inclusion of all elective terminations, 
lower bound estimates did not change for 15 estimates and changed by fewer than 5 cases 
per 1,000 for all defects except anencephaly, encephalocele, limb-body-wall complex, and 
amniotic band syndrome with craniofacial deformities (Appendix 7, available online at 
http://links.lww.com/AOG/B669). Upper bound estimates, did not change for three defects, 
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changed by 1–10 cases per 1,000 for 11 defects, by 11–50 cases for seven defects, and by 
more than 50 for anencephaly, encephalocele, and amniotic band syndrome with craniofacial 
deformities. The greatest changes in lower and upper bounds were for anencephaly (absolute 
change in lower and upper bounds: 268 and 940/1,000, respectively).
DISCUSSION
In this study we estimated the risks of stillbirth for specific birth defects and phenotypes, 
including many for which there are limited published data.6,14,17,31 These estimates may be 
of immediate value for informing referral to specialist care, including centers with expertise 
in prenatally diagnosed birth defects, informing prenatal monitoring, and counseling parents.
In our study, the overall birth defect-specific stillbirth risk ranged from 11 per 1,000 to 490 
per 1,000 affected fetuses; for comparison, these risks are 2–82 times higher than the overall 
stillbirth risk in the general population of pregnancies in the United States (6/1,000 fetuses).3 
Compared with the well-established 10 per 1,000 fetuses stillbirth risk associated with 
advanced maternal age (35 years or older), only fetuses with isolated cleft lip or palate had a 
lower risk of stillbirth.3 Among those with survivable isolated birth defects, we found that 
defects affecting the abdominal wall (omphalocele, gastroschisis, and cloacal exstrophy) 
generally had higher risks of stillbirth than defects affecting the central nervous system 
(holoprosencephaly, spina bifida, encephalocele, and Dandy-Walker malformation). 
However, consideration of potential bias due to termination suggested that risks for most 
defects in these two groups are likely similar.
We found elevated risks among fetuses with an expected low risk of stillbirth: those with 
isolated birth defects with greater than 98% neonatal survival—in particular cleft lip with 
cleft palate and limb defects (1.6–11 times higher than U.S. general population).19 Although 
the mechanisms driving these increased risks are unclear, our findings suggest that other 
factors alone or in combination with the birth defect may increase the risk of stillbirth. One 
possibility is that the cause of the birth defects may independently increase the risk of 
stillbirth; for example amniotic bands can entrap the umbilical cord, cutting off blood flow 
to the fetus.32–34 This may partially explain why some of the highest stillbirth risks 
identified in this study were among amniotic band-associated birth defects. An additional 
examples are maternal prepregnancy diabetes and undiagnosed genetic or chromosomal 
disorders which are strongly associated with both birth defects and stillbirth.35,36 Another 
possibility is that fetuses with any form of structural defect, relative to those who are 
normally formed, may be more vulnerable to additional stressors, such as maternal illness or 
obstetric complications.37
Nonetheless, our results provide some reassurance for parents and providers, because most 
fetuses with the examined birth defects survive to live birth and our results provide import 
information on the likelihood of survival to live birth for counseling parents of fetuses with a 
perinatal lethal defect. Additionally, knowledge of stillbirth risk for a fetus with a prenatally-
diagnosed birth defect may be useful in implementing enhanced prenatal monitoring, 
expedited delivery and other preventive measures in high-risk pregnancies.11,12,38 Although 
there is little research on prevention of stillbirth for most birth defects, multiple studies have 
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found enhanced monitoring and expedited delivery to be associated with lower risks of 
stillbirth among fetuses with gastroschisis.10–14 However, as with monitoring in pregnancies 
without a fetal malformation, rigorous research is needed to develop effective strategies.38
Our study has several limitations. Although the overall sample size is large, data were 
limited for specific birth defects and subtypes. Data were captured over a 14-year period; 
thus, our estimates represent an average risk over this time. The exclusion of cases with 
chromosomal and single gene disorders meant that we were unable to generate estimates for 
fetuses with these conditions. However, most birth defect cases are not known to be 
associated with chromosomal and single gene disorders.39 We did not require confirmed 
chromosomal testing as the poor success of available methods (ie, karyotype) among 
stillbirths would disproportionately exclude these cases, leading to an underestimate of 
stillbirth risk. Because genetic testing was not universal and testing methods during this time 
period were limited, some included cases may have unidentified genetic or chromosomal 
conditions. This limitation may particularly affect estimates for omphalocele as this defect is 
associated with various chromosomal disorders.40 However, strongly-suspected genetic or 
chromosomal cases were excluded after geneticist review and eligibility criteria changed 
throughout the course of the study as new associations with single gene disorders were 
discovered which should limit the potential influence of these disorders.20
We were unable to examine the severity of individual birth defects; thus, our estimates 
represent an average risk across the full severity range of examined birth defects. Elective 
terminations for birth defects are incompletely captured by birth defect surveillance and 
were not enrolled by one study site for one year and another site for all years.20 Therefore, 
the true risk bounds may be larger than our estimates. However, results of our sensitivity 
analysis suggest that at least a doubling of elective terminations would be needed to result in 
clinically meaningful changes in risk bounds.
Identification of birth defects among stillborn and terminated fetuses may be incomplete, 
particularly in the absence of autopsy. Consequently, if co-occurring birth defects remained 
undiagnosed, our results may underestimate risks for birth defects with decreased prenatal 
identification in addition to overestimating risks for isolated cases. However, most major 
birth defects among stillbirths are also identified by means other than autopsy.23 In contrast 
to prior studies, we did not calculate estimates for defects with poor sensitivity of prenatal 
diagnosis, thus avoiding the misleading suggestion of low stillbirth risks (eg, 0% for 
congenital cataract and choanal atresia).17
Our study builds on prior research by using a very large population-based cohort which 
includes detailed clinical geneticist review of all cases.5–7 Additionally, we present estimates 
of stillbirth risks for some very rare birth defects (ie, cloacal and bladder exstrophy, sacral 
agenesis, Dandy-Walker malformation) and phenotype-specific stillbirth risks within birth 
defect categories (eg, transverse limb deficiency).16,17 Use of a population-based cohort 
avoids bias due to referral patterns that may affect single center or hospital network-based 
studies.5,41 Importantly, quantification of potential bias due to elective termination allowed 
us to identify birth-defect specific risk estimates which may be biased to a clinically relevant 
degree and bounds improve comparability across areas with differing rates of termination for 
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birth defects. Furthermore, providing the maximum possible risk within the observed data 
may allow clinicians to account for the range of plausible estimates when determining 
appropriate clinical care. Although we are unable to provide direct estimates for fetuses with 
multiple birth defects, the risk of stillbirth for these fetuses will likely be similar to that of 
the highest risk defect present.
Although there are few studies with which to compare our results, our findings are broadly 
consistent with previous reports.6,16,17 Therefore, results of our study–and in particular the 
risk bounds–are expected to generalize to other high-income countries; risks may be further 
elevated in middle- and low-income countries, depending on local context (eg, access to 
medical care).
In conclusion, we found that the stillbirth risk for the birth defects examined was increased. 
Our estimates may inform counseling, referral to specialists, and clinical care after prenatal 
diagnosis. Further evidence on birth defect-specific associated conditions and causes of 
stillbirth, risk by gestational age, modifiable risk factors, and clinical care measures is 
needed to advance stillbirth prevention for fetuses with major birth defects.
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Fig. 1. 
Flow diagram of study cohort. *Included in sensitivity analysis.
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Fig. 2. 
Overall stillbirth risk for specific birth defects. This figure shows the number of stillbirths, 
births, and total cases, as well as the estimated stillbirth risk (closed circle), risk bounds 
(lower bound, open right arrow; upper bound, open left arrow), and 95% CIs (gray bar); all 
estimates are reported per 1,000 affected fetuses. Risks were calculated when there were at 
least 10 births in a specific birth defect category. Two-tailed 95% CIs using the Poisson 
distribution were used when there were fewer than 20 stillbirths, using the exact binomial 
method otherwise. Neonates and fetuses with multiple birth defects are included in the 
analysis for each primary birth defect for which they meet the eligibility criteria. ABS, 
amniotic band syndrome. Total births5stillbirths+live births; risk of stillbirth5stillbirths/live 
birth+stillbirths; upper risk bound5stillbirth+terminations/ live births+stillbirths
+terminations; lower risk bound5stillbirth/live births+stillbirths+terminations.
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Fig. 3. 
Stillbirth risk for isolated cases of specific birth defects. This figure shows the number of 
stillbirths, births, and total cases, as well as the estimated stillbirth risk (closed circle), risk 
bounds (lower bound, open right arrow; upper bound, open left arrow), and 95% CIs (grey 
bar); all estimates are reported per 1,000 affected fetuses. Risks were calculated when there 
were at least 10 births in a specific birth defect category. Two-tailed 95% CIs using the 
Poisson distribution were used when there were fewer than 20 stillbirths, using the exact 
binomial method otherwise. Because this analysis is restricted to isolated cases, neonates 
and fetuses are included only once. ABS, amniotic band syndrome. Total births5stillbirths
+live births; risk of stillbirth5stillbirths/live births+stillbirths; upper risk bound5stillbirth
+terminations/live births+stillbirths+terminations; lower risk bound5stillbirth/live births
+stillbirths+terminations.
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